0.91
-0.08%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About NovaBridge Biosciences
Its shares trade under the ticker NBP. It has been listed since 17 January 2020.
I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Jan 2020
- Employees
- 25
- Website
- i-mabbiopharma.com/en ↗
- Head office
- SUITE 400, 2440 RESEARCH BLVD, ROCKVILLE, MD, 20850
- Incorporated in
- E9
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer
Leadership
Pay as last reported
- Mr. Wei FuExecutive Chairman of the Board, since 2018
- Dr. Xi-Yong FuChief Executive Officer, Director, since 2024
- Dr. Emmett CunninghamVice Chairman of the Board, since 2026
- Mr. Kyler LeiChief Financial Officer
- Mr. Claire XuSenior Vice President - Clinical Development
- Dr. Sean CaoChief Business Development Officer, Director, since 2025
- Dr. Phillip DennisChief Medical Officer
- Mr. Chun Kwok AuIndependent Director
- Dr. Robert LenzIndependent Director
- Ms. Xin LiuIndependent Director
- Mr. Chia-Hung YangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 27
- Environment
- 12
- Social
- 46
- Governance
- 22
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong portfolio of innovative and potential breakthrough therapies in the biopharmaceutical industry.
- Strategic partnerships and collaborative agreements with leading global pharmaceutical companies, enhancing research and development capabilities.
- Established presence and reputation in the Chinese pharmaceutical market, a rapidly growing segment.
Weaknesses
- Relatively small scale compared to larger pharmaceutical companies, limiting resources and competitive advantage.
- High dependence on successful clinical trials and regulatory approvals, which pose significant risks to product development.
- Limited global footprint beyond Chinese market, potentially impacting market reach and market penetration.
Opportunities
- Growing global demand for innovative therapies presents opportunities for I-Mab to expand its market share outside of China.
- Increasing government support and favorable policies in China encourage domestic biopharmaceutical companies like I-Mab to further invest in research and development.
- Collaborative partnerships with academic institutions and research centers can provide access to additional expertise, resources, and potential breakthroughs.
Threats
- Intense competition from both domestic and international pharmaceutical companies in the biopharmaceutical market.
- Regulatory uncertainties and stringent approval processes in different markets may delay or hinder product commercialization.
- Potential challenges in intellectual property protection and patent disputes may affect the company's ability to maximize the value of its innovations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.